OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature
M. Munera‐Campos, F. Ballescà, J.M. Carrascosa
Actas Dermo-Sifiliográficas (2018) Vol. 109, Iss. 9, pp. 791-800
Open Access | Times Cited: 31
M. Munera‐Campos, F. Ballescà, J.M. Carrascosa
Actas Dermo-Sifiliográficas (2018) Vol. 109, Iss. 9, pp. 791-800
Open Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
Risk Factors for the Development of Psoriasis
Koji Kamiya, Megumi Kishimoto, Junichi Sugai, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4347-4347
Open Access | Times Cited: 490
Koji Kamiya, Megumi Kishimoto, Junichi Sugai, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4347-4347
Open Access | Times Cited: 490
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments
Carlo Alberto Maronese, Matthew A. Pimentel, May M. Li, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 5, pp. 615-634
Open Access | Times Cited: 146
Carlo Alberto Maronese, Matthew A. Pimentel, May M. Li, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 5, pp. 615-634
Open Access | Times Cited: 146
Bullous Pemphigoid: Trigger and Predisposing Factors
Francesco Moro, Luca Fania, Jo Linda Sinagra, et al.
Biomolecules (2020) Vol. 10, Iss. 10, pp. 1432-1432
Open Access | Times Cited: 132
Francesco Moro, Luca Fania, Jo Linda Sinagra, et al.
Biomolecules (2020) Vol. 10, Iss. 10, pp. 1432-1432
Open Access | Times Cited: 132
Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis
Farzad Alinaghi, Hasan Göcker Tekin, Johan Burisch, et al.
Journal of Crohn s and Colitis (2019) Vol. 14, Iss. 3, pp. 351-360
Closed Access | Times Cited: 83
Farzad Alinaghi, Hasan Göcker Tekin, Johan Burisch, et al.
Journal of Crohn s and Colitis (2019) Vol. 14, Iss. 3, pp. 351-360
Closed Access | Times Cited: 83
Pyoderma gangrenosum treated with secukinumab: A case report
Meghan L. McPhie, Mark G. Kirchhof
SAGE Open Medical Case Reports (2020) Vol. 8
Open Access | Times Cited: 29
Meghan L. McPhie, Mark G. Kirchhof
SAGE Open Medical Case Reports (2020) Vol. 8
Open Access | Times Cited: 29
Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis
Wentao Shi, Ziyi Zhao, Yinghong Zhai, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Wentao Shi, Ziyi Zhao, Yinghong Zhai, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Tumor necrosis factors‐α inhibition‐induced paradoxical psoriasis: A case series and literature review
Ni Lian, Li Zhang, Min Chen
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 21
Ni Lian, Li Zhang, Min Chen
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 21
Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy
Αναστάσιος Καραμανάκος, Theognosia Vergou, Stylianos Panopoulos, et al.
European Journal of Dermatology (2021) Vol. 31, Iss. 3, pp. 307-317
Closed Access | Times Cited: 19
Αναστάσιος Καραμανάκος, Theognosia Vergou, Stylianos Panopoulos, et al.
European Journal of Dermatology (2021) Vol. 31, Iss. 3, pp. 307-317
Closed Access | Times Cited: 19
New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature
Lula María Nieto‐Benito, Ofelia Baniandrés
Clinical Drug Investigation (2020) Vol. 40, Iss. 11, pp. 1089-1091
Closed Access | Times Cited: 14
Lula María Nieto‐Benito, Ofelia Baniandrés
Clinical Drug Investigation (2020) Vol. 40, Iss. 11, pp. 1089-1091
Closed Access | Times Cited: 14
Drug‐induced psoriasiform alopecia associated with interleukin‐17 inhibitor therapy
Timothy L. Tan, Lauren Taglia, Pedram Yazdan
Journal of Cutaneous Pathology (2021) Vol. 48, Iss. 6, pp. 771-774
Closed Access | Times Cited: 12
Timothy L. Tan, Lauren Taglia, Pedram Yazdan
Journal of Cutaneous Pathology (2021) Vol. 48, Iss. 6, pp. 771-774
Closed Access | Times Cited: 12
New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration
Hong-jiao Qi, Linfeng Li
BioMed Research International (2021) Vol. 2021, pp. 1-13
Open Access | Times Cited: 11
Hong-jiao Qi, Linfeng Li
BioMed Research International (2021) Vol. 2021, pp. 1-13
Open Access | Times Cited: 11
Cutaneous Vasculitis During Secukinumab Treatment
Camila da Silva Cendon Duran, Mittermayer Barreto Santiago
European Journal of Case Reports in Internal Medicine (2020), Iss. LATEST ONLINE
Open Access | Times Cited: 10
Camila da Silva Cendon Duran, Mittermayer Barreto Santiago
European Journal of Case Reports in Internal Medicine (2020), Iss. LATEST ONLINE
Open Access | Times Cited: 10
Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
Reem Kashlan, Kristin Slater, Martin E. Garber, et al.
JAAD Case Reports (2021) Vol. 10, pp. 47-49
Open Access | Times Cited: 9
Reem Kashlan, Kristin Slater, Martin E. Garber, et al.
JAAD Case Reports (2021) Vol. 10, pp. 47-49
Open Access | Times Cited: 9
Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient
Koray Durmaz, Arzu Ataseven, İlkay Özer
Dermatologic Therapy (2020) Vol. 33, Iss. 4
Open Access | Times Cited: 7
Koray Durmaz, Arzu Ataseven, İlkay Özer
Dermatologic Therapy (2020) Vol. 33, Iss. 4
Open Access | Times Cited: 7
Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study
Filiz Topaloğlu Demir, Tuğba Özkök Akbulut, İlknur Kıvanç Altunay, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 7
Filiz Topaloğlu Demir, Tuğba Özkök Akbulut, İlknur Kıvanç Altunay, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 6
Open Access | Times Cited: 7
Expression of microRNA‐21 and TIMP‐3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents
Raquel Navarro, Yolanda Delgado‐Jiménez, Juan Guinea‐Viniegra, et al.
Journal of Cutaneous Pathology (2021) Vol. 49, Iss. 2, pp. 116-122
Closed Access | Times Cited: 7
Raquel Navarro, Yolanda Delgado‐Jiménez, Juan Guinea‐Viniegra, et al.
Journal of Cutaneous Pathology (2021) Vol. 49, Iss. 2, pp. 116-122
Closed Access | Times Cited: 7
Subacute thyroiditis in a patient with psoriatic arthritis switched from secukinumab to adalimumab: a case report and literature review
Jun Nakagawa, Keita Fujikawa, Midori Akagi, et al.
Modern Rheumatology Case Reports (2020) Vol. 5, Iss. 1, pp. 36-39
Closed Access | Times Cited: 4
Jun Nakagawa, Keita Fujikawa, Midori Akagi, et al.
Modern Rheumatology Case Reports (2020) Vol. 5, Iss. 1, pp. 36-39
Closed Access | Times Cited: 4
Acute sarcoid myopathy and neuropathy aggravated by ustekinumab administration in an elderly woman with psoriasis and systemic sarcoidosis
Hironori Sano, Toshihiko Maeda, Ryota Sato, et al.
Rinsho Shinkeigaku (2022) Vol. 62, Iss. 6, pp. 475-480
Open Access | Times Cited: 3
Hironori Sano, Toshihiko Maeda, Ryota Sato, et al.
Rinsho Shinkeigaku (2022) Vol. 62, Iss. 6, pp. 475-480
Open Access | Times Cited: 3
Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?
Sohyeon Kim, Mi‐Yeon Eun, Hung Youl Seok
Neurological Sciences (2023) Vol. 44, Iss. 8, pp. 2981-2982
Closed Access | Times Cited: 1
Sohyeon Kim, Mi‐Yeon Eun, Hung Youl Seok
Neurological Sciences (2023) Vol. 44, Iss. 8, pp. 2981-2982
Closed Access | Times Cited: 1
Pathogenesis, molecular mechanism and treatment approaches of psoriasis: An update
Gagandeep Kaur, Sukhanpreet Kaur, Ruhi Rana, et al.
AIP conference proceedings (2024) Vol. 3007, pp. 030051-030051
Open Access
Gagandeep Kaur, Sukhanpreet Kaur, Ruhi Rana, et al.
AIP conference proceedings (2024) Vol. 3007, pp. 030051-030051
Open Access
A Case of Paradoxical Acneiform Eruption Triggered by Ixekizumab
Fidan BENER
Turkiye Klinikleri Journal of Case Reports (2024) Vol. 32, Iss. 2, pp. 32-35
Open Access
Fidan BENER
Turkiye Klinikleri Journal of Case Reports (2024) Vol. 32, Iss. 2, pp. 32-35
Open Access
A Case of Psoriatic Arthritis and Sarcoidosis Treated with Anti-IL-23 Monoclonal Antibody
Mirai HOTTA, Megumi MURAKAMI, Eri SAKAIDA, et al.
The Nishinihon Journal of Dermatology (2024) Vol. 86, Iss. 2, pp. 133-135
Closed Access
Mirai HOTTA, Megumi MURAKAMI, Eri SAKAIDA, et al.
The Nishinihon Journal of Dermatology (2024) Vol. 86, Iss. 2, pp. 133-135
Closed Access
Comparative study of paradoxical and classical psoriasis: what are clinical and therapeutic differences?
Yusuf Demi̇r, Tümay Ak, Sera Nur Yücesoy, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 6
Closed Access
Yusuf Demi̇r, Tümay Ak, Sera Nur Yücesoy, et al.
Archives of Dermatological Research (2024) Vol. 316, Iss. 6
Closed Access
Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors
D Costin, Alexandra Burlui, Anca Cardoneanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7018-7018
Open Access
D Costin, Alexandra Burlui, Anca Cardoneanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7018-7018
Open Access
Paradoxical psoriasis with IL-17 inhibitors
Shikha Singla, Dimitri Luz
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 3
Open Access
Shikha Singla, Dimitri Luz
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 3
Open Access
